The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer

M. Adams, H. Navabi, D. Croston, S. Coleman, Z. Tabi, A. Clayton, B. Jasani, M. D. Mason

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)

Abstract

A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.

Original languageEnglish
Pages (from-to)2374-2378
Number of pages5
JournalVaccine
Volume23
Issue number17-18
DOIs
Publication statusPublished - Mar 18 2005

Keywords

  • Ovarian cancer
  • TLR3
  • Tumour-derived exosomes
  • Tumour-specific T cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this